Multiple myeloma trials in Canada

In Canada 48 Also abroad 703

48 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Not yet taking people in Canada
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Where
Edmonton, Halifax, London, Montreal, Ottawa, Toronto
Age
18 years to 100 years
People
108
Run by
Canadian Myeloma Research Group
See details and how to joinNCT07831122
Phase 1/2Taking people
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Calgary, Halifax, Toronto, Vancouver
Age
18 years and over
People
62 worldwide
Run by
Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00
Phase 2Taking people
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Where
Edmonton, Halifax, London, Montreal, St. John's, Toronto
Age
65 years and over
People
75
Run by
Canadian Myeloma Research Group
See details and how to joinNCT05272826
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Calgary, Edmonton, Halifax, Hamilton, Montreal, Saskatoon, Toronto
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Moncton, Montreal
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Calgary, Halifax, Montreal, Ottawa, Sherbrooke, Vancouver
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
Phase 3Not yet taking people in Canada
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
London, Montreal, Victoria
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00
Phase 4Taking people
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Where
Lévis, Québec
Age
18 years and over
People
80
Run by
CHU de Quebec-Universite Laval
See details and how to joinNCT07094048
Phase 1Taking people
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Calgary, Toronto
Age
18 years and over
People
187 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06121843
Phase 1/2Taking people
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Where
Calgary, Edmonton, Halifax, Montreal, St. John's, Toronto, Vancouver, Winnipeg
Age
18 years and over
People
300 worldwide
Run by
Karyopharm Therapeutics Inc
See details and how to joinNCT02343042
Phase 4Taking people
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Where
Calgary, Edmonton, Montreal
Age
18 years and over
People
80 worldwide
Run by
Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00
Phase 1Taking people
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
Where
Toronto
Age
18 years and over
People
20
Run by
University Health Network, Toronto
See details and how to joinNCT07456605
Phase 1Taking people
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Where
Montreal, Toronto
Age
18 years and over
People
135 worldwide
Run by
AbbVie
See details and how to joinNCT06896916 · EU 2024-512146-41-00
No phaseTaking people
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Where
Edmonton
Age
18 years to 90 years
People
75
Run by
University of Alberta
See details and how to joinNCT05645510
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Saint John
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
Phase 2Taking people
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Where
Edmonton, Kelowna, Kingston, London, Montreal, Ottawa, Regina, Saskatoon, Toronto, Vancouver
Age
18 years and over
People
720
Run by
Canadian Cancer Trials Group
See details and how to joinNCT03297606
Phase 1Taking people
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Where
Montreal, Sherbrooke, Vancouver
Age
18 years and over
People
87 worldwide
Run by
Sanofi
See details and how to joinNCT06630806
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Calgary, Edmonton
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
Phase 4Taking people
Plan Development for Giving Teclistamab in the Outpatient Setting
Where
Toronto
Age
18 years and over
People
15
Run by
University Health Network, Toronto
See details and how to joinNCT06251076
No phaseTaking people
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Where
Toronto
Age
18 years and over
People
144
Run by
University Health Network, Toronto
See details and how to joinNCT06485076
Phase 1/2Taking people
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Where
Calgary, Edmonton, Toronto
Age
18 years and over
People
260 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT05372354 · EU 2023-509384-25-00
No phaseTaking people
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
Where
Montreal
Age
18 years and over
People
70
Run by
Sir Mortimer B. Davis - Jewish General Hospital
See details and how to joinNCT05530096
No phaseNot yet taking people in Canada
Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer
Where
Montreal
Age
18 years and over
People
60
Run by
Ciusss de L'Est de l'Île de Montréal
See details and how to joinNCT06817759